Galcanezumab

Galcanezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCALCA, CALCB
Clinical data
Trade namesEmgality
Other namesLY2951742, galcanezumab-gnlm
AHFS/Drugs.comMonograph
MedlinePlusa618063
License data
Routes of
administration		Subcutaneous
Drug classCalcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6392H9854N1686O2018S46
Molar mass144083.69 g·mol−1

Galcanezumab,[4][5] sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[2] It is also used for the treatment of cluster headaches.[6]

A substance called calcitonin gene-related peptide (CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain.[3] Galcanezumab is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size.[3] This will stop the symptoms of migraine.[3] Galcanezumab is generally delivered through self-injections.[7] Common side effects include injection site reactions such as pain or redness.[6][3] Other side effects may include hypersensitivity reactions.[6]

Galcanezumab was developed by Eli Lilly.[8] It was approved for medical use in the United States and in the European Union in 2018,[9][10][3] becoming the third calcitonin gene-related peptide (CGRP) inhibitor to be approved by the US Food and Drug Administration (FDA).[11]

  1. ^ "Summary Basis of Decision (SBD) for Emgality". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ a b "Emgality- galcanezumab-gnlm injection, solution". DailyMed. 11 March 2021. Retrieved 29 April 2024.
  3. ^ a b c d e f Cite error: The named reference Emgality EPAR was invoked but never defined (see the help page).
  4. ^ "Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.
  5. ^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.
  6. ^ a b c "FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks" (Press release). U.S. Food and Drug Administration (FDA). 4 June 2019. Archived from the original on 7 December 2019. Retrieved 6 June 2019. This article incorporates text from this source, which is in the public domain.
  7. ^ "Galcanezumab-gnlm Injection: MedlinePlus Drug Information". medlineplus.gov. Retrieved 26 July 2024.
  8. ^ Spreitzer H (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
  9. ^ "Drug Approval Package: Emgality (galcanezumab-gnlm)". U.S. Food and Drug Administration (FDA). 27 September 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019.
  10. ^ "Drug Trials Snapshots: Emgality". U.S. Food and Drug Administration (FDA). 23 October 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.
  11. ^ "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.